Can tracking antibiotic levels in the blood improve sepsis care?

NCT ID NCT05413343

Ongoing Knowledge-focused Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This study is tracking how the antibiotic ceftazidime-avibactam behaves in the blood of critically ill patients with severe sepsis. Researchers are collecting blood samples at several time points to measure drug levels and build a model that could help doctors choose the right dose. The goal is to develop better dosing guidelines for patients with different kidney function, including those on dialysis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ceftazidime-avibactam
What this could lead to: If successful, this could lead to more precise dosing of ceftazidime-avibactam for critically ill sepsis patients, potentially improving treatment outcomes.
What could go wrong: This is a small observational study with only 30 participants, so findings may not apply to all patients. It measures drug levels but does not test a new treatment or directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE SEPSIS

Contacts and locations

Locations

The First Affiliated Hospital,College of Medicine,Zhejiang University

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.